



ATCCS 2025

BEYOND THE HORIZON

Asia Thoracic Cancer Care Summit



19th - 20th June, 2025 · HONG KONG

Daniel H STERMAN

Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine

Department of Medicine

Professor

Department of Cardiothoracic Surgery

NYU Grossman School of Medicine

USA

Daniel H. Sterman, M.D., is the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine in the Departments of Medicine and Cardiothoracic Surgery at the New York University Grossman School of Medicine, Director of the Division of Pulmonary, Critical Care, and Sleep Medicine, and Director of the Multidisciplinary Pulmonary Oncology Program at NYU Langone Health in New York City. He was previously lead clinical investigator in the multidisciplinary Thoracic Oncology Research Group at the Perelman School of Medicine at the University of Pennsylvania and the Principal Investigator of the Clinical Trials Project for the Penn NCI thoracic oncology program project grant from 1997-2015.

Dr. Sterman's research interests are related to the development of cutting-edge treatments for thoracic malignancies, specifically as they apply to the synergy of molecular medicine, tumor immunotherapy and novel technologies in Interventional Pulmonology. Over the past 30 years, he has focused on the translation of laboratory discoveries from the bench to the bedside: conducting multiple human clinical trials of gene-based, oncolytic viral, cellular and vaccine therapies for lung cancer, mesothelioma, and other pleural malignancies. He has served as principal investigator of multiple clinical trials of intracavitary gene delivery in patients with pleural malignancies and is an international expert in this emerging field.

As Director of the NYU PORT (Pulmonary Oncology Research Team), Dr. Sterman has expanded his research interests into further evaluation of local intra-tumoral and intra-nodal immunotherapies utilizing state-of-the-art endoscopic modalities, including robotics and endobronchial ultrasound. He served as co-national principal investigator of the LuTK02 clinical trial of intra-tumoral oncolytic viral immunotherapy in patients with advanced non-small cell lung cancer refractory to immune checkpoint inhibition, as well as global principal investigator of the INFINITE clinical trial, a randomized Phase III clinical trial of intra-pleural adenovirus-interferon alpha 2b gene transfer in combination with chemotherapy as second/third line therapy for pleural mesothelioma. In addition, he leads a National Cancer Institute funded translational program of bronchoscopic cryo-immunotherapy for adjunctive treatment of non-small cell lung cancer.

Dr. Sterman's research interests also extend into the evaluation of immune responses to other ablative modalities for peripheral lung tumors, including pulsed electrical fields (PEF), as well as in the multi-omic analysis of immune microenvironments within the primary tumor, tumor-draining lymph nodes, and in the peripheral circulation.